

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau




(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/101506 A1

- (51) International Patent Classification⁷: **C07C 323/62**,
C07D 213/70, 333/38, A61K 31/10, 31/44, 31/4436,
31/381, A61P 35/00
- (74) Agents: WATSON, Robert et al.; Mewburn Ellis LLP,
York House, 23 Kingsway, London Greater London WC2B
6HP (GB).
- (21) International Application Number:
PCT/GB2004/002101
- (22) International Filing Date: 14 May 2004 (14.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0311195.2 15 May 2003 (15.05.2003) GB
- (71) Applicant (for all designated States except US):
CHROMA THERAPEUTICS LIMITED [GB/GB];
92 Milton Park, Abingdon Oxfordshire OX14 4RY (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **ASHTON, Mark**
[GB/GB]; Evotec OAI Limited, 151 Milton Park, Abing-
don Oxfordshire OX14 4SD (GB). **DAVIDSON, Alan**
[GB/GB]; Chroma Therapeutics Limited, 92 Milton Park,
Abingdon Oxfordshire OX14 4RY (GB). **THOMAS,**
Russell [GB/GB]; Evotec OAI Limited, 151 Milton Park,
Abingdon Oxfordshire OX14 4SD (GB). **WHITTAKER,**
Mark [GB/GB]; Evotec OAI Limited, 151 Milton Park,
Abingdon Oxfordshire OX14 4SD (GB).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.
- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: GLYOXALASE INHIBITORS



(57) Abstract: This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase I. Wherein X is N or CH. R² is H, CF₃, or optionally substituted C₅₋₆ aryl, C₃₋₇ cycloalkyl, C₅₋₇ heterocyclyl. R³ is H; or optionally substituted C₅₋₆ aryl, C₃₋₇ cycloalkyl, C₅₋₇ heterocyclyl. Alternatively R² and R³ together form an optionally substituted C₃₋₄alkylene group wherein L³ and L⁴ are single bonds thus forming a C₅₋₆ ring fused with the aromatic ring to which L³ and L⁴ are attached. L³ and L⁴ are independently selected from a single bond, optionally substituted C₁₋₄ alkylene, -L⁹YN(OH)C(=O)L¹⁰, and -L⁹C(=O)N(OH)YL¹⁰, wherein L⁹ and L¹⁰ are independently selected from optionally substituted C₁₋₄ alkylene, C₅₋₆ arylene, C₁₋₄ alkylene-C₅₋₆arylene and a single bond, wherein Y is NH or a single bond.